cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Sol Gel Technologies Ltd
2 watching
Current Price
$0
$0.18
(3.65%)
logo-slgl
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
114.03M
52-Week High
52-Week High
8.0815
52-Week Low
52-Week Low
3.94
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization114.03M
icon52-Week High8.0815
icon52-Week Low3.94
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Sol Gel Technologies Ltd do?
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Read More
News & Events about Sol Gel Technologies Ltd.
Globe Newswire
4days ago
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a dermatology company with FDA approvals for EPSOLAY and TWYNEO, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022, announced ...
Globe Newswire
4days ago
Patidegib, an Orphan Drug candidate, broadens Sol-Gels pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3 study expected to initiate in the second half of 2023, with results expected by the end of ...
Globe Newswire
2 months ago
Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gels cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology ...
Ticker Report
3 months ago
Jefferies Financial Group began coverage on shares of Sol-Gel Technologies (NASDAQ:SLGL Get Rating) in a report issued on Friday morning, The Fly reports. The brokerage issued a hold rating and a $5.50 price objective on the stock. Separately, HC Wainwright increased their price objective on...
PR Newswire
8 months ago
Galderma Launches EPSOLAY Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea Galderma Launches EPSOLAY Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea PR Newswire FORT WORTH, Texas, June 2, 2022 FDA-approved EPSOLAY (benzoyl peroxide) Cream, 5% is now available by...
Frequently Asked Questions
Frequently Asked Questions
What is Sol Gel Technologies Ltd share price today?
plus_minus_icon
Can Indians buy Sol Gel Technologies Ltd shares?
plus_minus_icon
How can I buy Sol Gel Technologies Ltd shares from India?
plus_minus_icon
Can Fractional shares of Sol Gel Technologies Ltd be purchased?
plus_minus_icon
What are the documents required to start investing in Sol Gel Technologies Ltd stocks?
plus_minus_icon
What is today’s traded volume of Sol Gel Technologies Ltd?
plus_minus_icon
What is today’s market capitalisation of Sol Gel Technologies Ltd?
plus_minus_icon
What is the 52-Week High and Low Range of Sol Gel Technologies Ltd?
plus_minus_icon
What percentage is Sol Gel Technologies Ltd down from its 52-Week High?
plus_minus_icon
What percentage is Sol Gel Technologies Ltd up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.18
(3.65%)
logo-slgl
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00